Azoulay, Elie http://orcid.org/0000-0002-8162-1508
,
Bauer, Philippe R.
Mariotte, Eric
Russell, Lene
Knoebl, Paul
Martin-Loeches, Ignacio
Pène, Frédéric
Puxty, Kathryn
Povoa, Pedro
Barratt-Due, Andreas
Garnacho-Montero, Jose
Wendon, Julia
Munshi, Laveena
Benoit, Dominique
von Bergwelt-Baildon, Michael
Maggiorini, Marco
Coppo, Paul
Cataland, Spero
Veyradier, Agnès
Van de Louw, Andry
Article History
Received: 5 July 2019
Accepted: 7 August 2019
First Online: 7 October 2019
Change Date: 21 January 2020
Change Type: Correction
Change Date: 21 January 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. The penultimate row of Table 4 shows INR > 1.5 which is incorrect. The correct figure is INR < 1.5. The authors apologize for the mistake. The correct table is given below.
Change Details: The original version of this article unfortunately contained a mistake. The penultimate row of Table��4 shows INR���>���1.5 which is incorrect. The correct figure is INR���<���1.5. The authors apologize for the mistake. The correct table is given below.
Compliance with ethical standards
:
: This statement is the result of independent work carried out by members of the Nine-i network of investigators. None of the authors received any honoraria or fees for this work. The Nine-i network has received research grants and sponsorships from Gilead, Fisher&Payckle, Jazz Pharma, Ablynx, Baxter, Alexion, and Astellas. Financial ties unrelated to this work are as follows. Over the last 3 years, EA received honoraria or travel expense reimbursements from Alexion, Baxter, MSD, Ablynx, Pfizer, and Gilead. IML has received honoraria or travel expense reimbursements from Biomerieux, MSD, and Gilead. AV sits on the advisory boards of Ablynx-Sanofi-Genzyme, Roche-Chugai, and Shire-Takeda. PC sits on the advisory boards of Alexion, Sanofi-Genzyme, Roche-Chugai, Octapharma, and Shire-Takeda. PP received honoraria or travel expense reimbursements from Pfizer and Orion. DB has received grants from Gilead, Astellas, Fisher-Paykel, Baxter, Alexion, and Fresenius Kabi. SC sits on the advisory boards of Alexion, Sanofi-Genzyme, and Shire-Takeda. FP and JGM have received fees from Alexion. None of the other authors has any potential conflicts of interest to declare.